X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Will AIDS drive Cipla's growth? - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Apr 27, 2000

    Will AIDS drive Cipla's growth?

    Cipla's topline growth has been an impressive 23% as against the overall growth of 9.2% for the overall formulation industry. This year the company has been aggressive in the unbranded generic market which to some extent has contributed to the turnover growth. These are mainly in the anti–infective segment and the anti–inflammatory segment where the company does not have well established brands. Here the company supplies to hospitals and nursing homes at discounted prices. This accounts for the reduced margins.

    (Rs m) FY1999 FY2000 Change
    Sales 6,172 7,593 23.0%
    Other Income 269 312 15.9%
    Expenditure 4,732 6,033 27.5%
    Operating Profit (EBDIT) 1,440 1,560 8.4%
    Operating Profit Margin (%) 23.3% 20.5%  
    Interest 29 11 -61.3%
    Depreciation 135 135 0.0%
    Profit before Tax 1,545 1,726 11.7%
    Other Adjustments      
    Tax 395 408 3.2%
    Profit after Tax/(Loss) 1,150 1,318 14.6%
    Net profit margin (%) 18.6% 17.4%  
    Earnings per share* 57.5 22.0  
    * Cipla issued a 2:1 bonus in the current year

    In the branded formulations the company launched non–CFC based inhalers for asthma under the brand name Asthalin HFA. These are expected to continue to lead growth in the future too since CFC based inhalers have to be compulsorily phased out by 2010. Another breakthrough for the company during the year was the manufacture and the marketing of an anti–AIDS pill, branded Nivimune. The company priced its tablet at Rs 135 per tablet as against Rs 344 for an imported tablet.

    Cipla’s strategy has been to develop products by reverse engineering and the introduction of the anti–AIDS medicine is an example of that. The patent on this medicine expires in 2010. However, since India does not have a patent law that recognises product patents Cipla can get away with the introduction of this drug.

    The stock currently quotes at Rs 1,004 at an earnings multiple of around 44 times, the highest earnings multiples the company has enjoyed over the last three years. One reason for this could be the expectation that compulsory licensing for the anti–AIDS drug (where companies other than the original patent holder can also sell the patented drug) could open up a big market for the company.

     

     

    Equitymaster requests your view! Post a comment on "Will AIDS drive Cipla's growth?". Click here!

      
     

    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CIPLA SHARE PRICE


    Aug 22, 2017 11:08 AM

    TRACK CIPLA

    CIPLA - BIOCON LTD COMPARISON

    Compare Company With Charts

    COMPARE CIPLA WITH

    MARKET STATS